Live feed08:30:00·183dPRReleasevia QuantisnowActinium Pharmaceuticals Presents New Data Demonstrating Potent and Durable Efficacy of ATNM-400, a First-in-Class Multi-Tumor Actinium-225 Radiotherapy, at the 32nd Annual Prostate Cancer Foundation Scientific RetreatByQuantisnow·Wall Street's wire, on your screen.ATNM· Actinium Pharmaceuticals Inc. (Delaware)Health Care
